{"id":18047,"date":"2026-07-31T09:31:20","date_gmt":"2026-07-31T09:31:20","guid":{"rendered":"https:\/\/www.eyecliniclondon.com\/blog\/?p=18047"},"modified":"2026-07-31T09:31:20","modified_gmt":"2026-07-31T09:31:20","slug":"future-tear-biomarkers-eye-care","status":"publish","type":"post","link":"https:\/\/www.eyecliniclondon.com\/blog\/future-tear-biomarkers-eye-care\/","title":{"rendered":"The Future of Tear Biomarkers in Eye Care"},"content":{"rendered":"

Your tears contain proteins, lipids, electrolytes and other biological molecules that can provide information about the ocular surface. Selected tear-based measurements are already used in some dry-eye assessments, while researchers are investigating much broader biomarker panels for conditions affecting the cornea, retina and optic nerve.<\/p>\n

Most advanced applications remain in the research or validation stage and should not replace a comprehensive eye examination, imaging or established screening. In the future, validated tear tests may add molecular information to your symptoms and clinical findings, but their value will depend on whether they improve real treatment and monitoring decisions.<\/p>\n

Why Tears Are Attracting Scientific Interest<\/h2>\n

Tears can be collected without a blood test or surgical procedure and contain molecules linked to inflammation, tear-film balance and ocular-surface health. This makes them attractive for research into tests that could be repeated more easily than some other biological investigations.<\/p>\n

However, tears are produced in very small volumes and their composition can change with collection technique, reflex watering, contact lenses, eye drops and environmental conditions. A useful clinical test therefore needs not only a promising biomarker but also a standardised method that produces consistent results in different clinics and patient groups.<\/p>\n

What Scientists Mean by a Tear Biomarker<\/h2>\n

A tear biomarker is a measurable substance in your tears that can provide information about your eye health or how your body responds to treatment. These biomarkers may include proteins, lipids, enzymes, hormones and other molecules that can reflect inflammation, tissue changes or other biological processes.<\/p>\n

Some current tear tests measure one feature, such as osmolarity or an inflammatory marker, while many research projects examine combinations of proteins, lipids, metabolites or genetic material. Measuring several biomarkers may eventually improve disease classification, but a larger panel is not automatically more accurate or clinically useful.<\/p>\n

How Are Tear Samples Collected?<\/h2>\n

Tear samples may be collected using an absorbent strip, a fine capillary tube or a small point-of-care collection device. The preferred method depends on the biomarker being measured, the amount of fluid required and whether the result will be analysed immediately or sent to a laboratory.<\/p>\n

Collection conditions matter because reflex tearing, eye drops, contact lenses, cosmetics, recent eye procedures and the time of collection may alter the sample. Clinical services and research studies therefore need clear preparation, collection, storage and quality-control procedures.<\/p>\n

Clinical Tip:<\/strong><\/p>\n

Follow the clinic\u2019s instructions about contact lenses, eye drops and cosmetics before a tear test, as these may affect collection or interpretation. Do not stop prescribed eye medication or change your usual treatment unless the ophthalmologist or clinical team specifically advises you to do so.<\/p>\n

What Is Tear Proteomics?<\/h2>\n

Proteomics uses laboratory techniques to study large numbers of proteins within a tear sample. Depending on the collection, equipment and analytical method, researchers may identify hundreds or thousands of protein signals and compare their patterns between people with and without a particular condition.<\/p>\n

This is primarily a research approach rather than a routine clinic test. Potential protein signatures must be reproduced in independent populations, linked to a meaningful clinical outcome and converted into a practical, quality-controlled test before they can reliably guide patient care.<\/p>\n

Research Insight:<\/strong><\/p>\n

A biomarker may appear different in a research group without being accurate enough for routine diagnosis. Translation requires independent replication, agreed collection methods, clinically meaningful thresholds and prospective studies showing that using the result improves patient management rather than simply separating two groups in a laboratory analysis.<\/p>\n

Could Multi-Omics Provide a More Complete Picture?<\/h2>\n

\"\"<\/p>\n

Multi-omics research combines information from proteins, lipids, metabolites and genetic material to explore several biological pathways at once. This may reveal disease patterns that would not be visible when researchers examine one type of molecule alone.<\/p>\n

The approach also generates complex data and increases the risk of finding patterns that do not remain accurate in another population. Larger prospective studies, standardised laboratory methods and transparent analytical models will be needed before multi-omic tear profiles can guide routine treatment.<\/p>\n

What Are Tear-Derived Extracellular Vesicles?<\/h2>\n

Extracellular vesicles are very small membrane-covered particles released by cells. They can carry proteins and genetic material, which makes tear-derived vesicles an interesting potential source of information about ocular and neurological disease.<\/p>\n

Research remains at an early translational stage. Collection, isolation and analysis methods are not yet sufficiently standardised for routine eye-care use, and larger studies are needed to determine whether vesicle measurements provide reliable information beyond existing examinations and scans.<\/p>\n

How Are Tear Biomarkers Already Used in Dry-Eye Assessment?<\/h2>\n

Dry eye is currently the clearest clinical application for selected tear measurements because the condition directly affects the tear film and ocular surface. Tear osmolarity and point-of-care inflammatory-marker tests may provide additional information in some clinics, but they must be interpreted alongside symptoms, tear stability, ocular-surface staining, eyelid assessment and other findings.<\/p>\n

More advanced protein and cytokine panels may eventually help distinguish different inflammatory or tear-film pathways and monitor response to treatment. These broader applications still require stronger validation, and no tear biomarker should be used alone to decide whether a patient has dry-eye disease or which treatment they need.<\/p>\n

Evidence Note:<\/strong><\/p>\n

Selected point-of-care tools, including tear osmolarity systems and MMP-9 immunoassays, are already available for dry-eye assessment in some clinical settings. These tests may provide supplementary information but should be interpreted alongside symptoms, tear stability, ocular-surface staining, eyelid assessment and other findings rather than used as stand-alone diagnostic tests. Advanced proteomic and multi-biomarker panels remain investigational.<\/p>\n

Myth vs Fact<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Myth<\/strong><\/td>\nFact<\/strong><\/td>\n<\/tr>\n<\/thead>\n
All tear biomarker tests are still experimental.<\/td>\nSelected tear osmolarity and inflammatory-marker tests are already used in some dry-eye services, while broader multi-omic and disease-prediction panels remain investigational.<\/td>\n<\/tr>\n
One abnormal tear biomarker can diagnose an eye condition.<\/td>\nA biomarker result must be interpreted with symptoms, examination findings and established tests.<\/td>\n<\/tr>\n
A tear test can replace OCT or corneal imaging.<\/td>\nTear analysis may provide molecular information, but imaging remains essential for showing structural changes in the cornea, retina and optic nerve.<\/td>\n<\/tr>\n
Measuring more biomarkers always produces a better diagnosis.<\/td>\nLarger panels can generate more information, but they also require validation, quality control and careful statistical analysis.<\/td>\n<\/tr>\n
Smart contact lenses are already providing continuous biomarker monitoring in routine care.<\/td>\nMost biochemical smart-contact-lens systems remain prototypes or research devices and must demonstrate comfort, safety, accuracy and regulatory compliance.<\/td>\n<\/tr>\n
A research result means that the test is available in UK clinics.<\/td>\nA test must complete clinical validation and meet relevant medical-device requirements before routine use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Could Tear Biomarkers Support Earlier Keratoconus Assessment?<\/h2>\n

Researchers are studying whether tear cytokines can add useful information to corneal tomography and machine-learning analysis. Early research suggests that combining tear biomarkers with clinical and Pentacam findings may improve model performance, but the approach remains investigational.<\/p>\n

These findings are promising but do not establish tear testing as a routine keratoconus-screening tool or an alternative to corneal topography or tomography. External and prospective validation in larger, more diverse populations is needed before the approach can be recommended for routine care.<\/p>\n

Could Tears Provide Information About Retinal Disease?<\/h2>\n

Researchers have reported differences in tear proteins, inflammatory molecules and genetic material in people with conditions such as diabetic retinopathy and age-related macular degeneration. These findings may improve understanding of disease biology and could eventually contribute to risk assessment or monitoring.<\/p>\n

The evidence remains exploratory and tear testing is not an alternative to diabetic eye screening, retinal photography, OCT or specialist retinal examination. Researchers must still demonstrate that a tear result reliably reflects retinal changes and improves decisions beyond established imaging.<\/p>\n

Could Tear Biomarkers Contribute to Glaucoma Research?<\/h2>\n

Researchers are investigating tear proteins and inflammatory markers associated with glaucoma, its treatments and changes at the ocular surface. This work may eventually help distinguish disease-related signals from the effects of long-term eye drops or identify people who need closer investigation.<\/p>\n

There is currently no routinely validated tear-biomarker test that predicts glaucoma progression or replaces eye-pressure measurement, optic-nerve assessment, visual-field testing or OCT. Larger longitudinal studies are needed to show that candidate markers change before or alongside clinically meaningful progression.<\/p>\n

How Artificial Intelligence Can Interpret Complex Tear Data<\/h2>\n

\"\"<\/p>\n

Artificial intelligence may help researchers analyse patterns across multiple tear biomarkers and combine them with imaging and other clinical information. This could eventually support disease classification or risk estimation, but strong performance in one research dataset does not show that a model will work reliably in another clinic or population.<\/p>\n

Before clinical use, an AI model requires external and prospective validation, assessment for bias, transparent reporting and evidence that its output improves meaningful clinical decisions or outcomes. Your ophthalmologist would still need to interpret the result in the context of your symptoms, examination and established investigations.<\/p>\n

Personalised Treatment Could Become More Practical<\/h2>\n

Eye specialists already personalise your treatment using your symptoms, examination findings, scans and medical history. Tear biomarkers may add another layer of information by showing which biological processes are most active in your condition, helping treatment become more targeted.<\/p>\n

In dry-eye care, selected tests may provide additional information about tear osmolarity or ocular-surface inflammation in some specialist settings. More complex biomarker profiles may eventually help classify biological subtypes or monitor treatment response, but they should not be used alone to select treatment. Symptoms, slit-lamp findings, tear stability, staining, eyelid and gland assessment and other established tests remain essential.<\/p>\n

Microfluidic Tests Could Bring the Laboratory Into the Clinic<\/h2>\n

Microfluidic devices are being developed to analyse very small tear samples and potentially provide results at or near the point of care. Possible advantages include lower sample-volume requirements, shorter turnaround times and the ability to measure several targets on one platform.<\/p>\n

Before routine use, each device requires analytical and clinical validation, suitable quality controls and evidence that faster results improve patient management. A rapid result is not clinically useful if collection is inconsistent or the decision threshold has not been validated in the intended patient population.<\/p>\n

Could Smart Contact Lenses Monitor Tears Continuously?<\/h2>\n

Researchers are developing contact lenses containing optical, electrochemical or microfluidic sensors that could measure tear constituents while the lens is worn. Proposed targets include electrolytes, glucose and selected proteins, but most biochemical smart-contact-lens systems remain prototypes or early-stage research devices rather than tools used in routine eye care.<\/p>\n

Continuous monitoring is technically challenging because the lens itself may affect the tear film, sensor signals may drift and measurements require reliable calibration. Comfort, oxygen transmission, data transmission, cleaning, long-term safety and regulatory compliance must also be demonstrated before these devices can be used clinically.<\/p>\n

What Could Slow Clinical Adoption?<\/h2>\n

Clinical adoption will depend on standardised collection and analysis, reproducible results across platforms, appropriate reference ranges and clear evidence that a test provides information beyond established examinations. Reflex tearing, sample volume, storage, eye drops, contact lenses, environmental conditions and systemic health may all influence a result.<\/p>\n

Practical requirements are equally important, including cost, staff training, point-of-care quality control, data protection, integration with imaging and medical records, device regulation and equitable access. Prospective multicentre studies and health-economic evaluation will be needed to show that testing improves management or patient outcomes.<\/p>\n

What Can You Realistically Expect From Tear Testing?<\/h2>\n

\"\"<\/p>\n

Selected tear tests are already available for particular ocular-surface questions, while advanced multi-biomarker tests for keratoconus, retinal disease, glaucoma and other conditions remain mainly within research. The likely future is therefore gradual expansion rather than one universal tear test that diagnoses every eye condition.<\/p>\n

Where a validated test is available, it should be used for a clearly defined purpose and interpreted alongside your symptoms, eye examination and appropriate imaging. Established screening and monitoring appointments should continue even when tear testing is offered.<\/p>\n

UK Guidance Note:<\/strong><\/p>\n

Depending on their intended purpose and design, tear-analysis products may be regulated as medical devices or in-vitro diagnostic medical devices. Products placed on the market in Great Britain must meet the applicable requirements of the UK Medical Devices Regulations and be registered with the MHRA where required. Registration does not represent MHRA approval, accreditation or endorsement. NICE has published Medtech Innovation Briefing MIB47 on tear osmolarity, but MIBs contain no recommendations and are not formal NICE guidance.<\/p>\n

Key Takeaways<\/h2>\n